LOS ANGELES, July 19 /PRNewswire-FirstCall/ -- Response Genetics, Inc. today announced that Company President and Chief Executive Officer Kathleen Danenberg will speak about cancer biomarkers and highlight Company data in colorectal, lung and pancreatic cancer at the Twenty-Second Aspen Cancer Conference Satellite Meeting, New Frontiers In Clinical Oncology 2007, in Aspen, Colorado, on Friday, July 20, at 8:50 a.m. Mountain Daylight Time. These data show that the Company’s proprietary and patented techniques for extracting RNA from formalin-fixed paraffin-embedded (FFPE) tissue samples are useful to predict short and long-term survival after therapy, as well as to differentiate metastatic and non-metastatic cancers. Ms. Danenberg will also present the recently-published data that suggests Excision-Repair Cross- Complementing 1 (ERCC-1) is a predictive biomarker for cisplatin sensitivity in lung cancer. Ms. Danenberg’s presentation will be made available on the Company’s website.
“It is a privilege to have the opportunity to present in front of a group of leading scientists at the forefront of cancer research,” said Ms. Danenberg. “At Response Genetics, we are very encouraged by our data, which show that we are gleaning meaningful gene expression and biological pathway data from microarrays with RNA extracted from FFPE samples. The goal is to use this pharmacogenomic information to predict patient outcomes to various therapies.”
About Response Genetics, Inc.
Response Genetics, Inc. (“RGI”) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the “Company”) related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as defining, targeting and individualizing therapies for cancer patients, the usefulness of the Company’s proprietary techniques for distinguishing between metastatic and non- metastatic cancers and predicting cancer survival rates after therapy, ERCC-1 as a predictive biomarker, and other statements identified by words such as “projects”, “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward- looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward- looking statements, whether because of new information, future events or otherwise, except as required by law.
Response Genetics, Inc.
CONTACT: Investor Relations - Christine Yang, of Trout Group,+1-646-378-2929; or Media Relations - Brad Miles, of BMC Communications,+1-212-477-9007 x17, both for Response Genetics, Inc.
Web site: http://www.responsegenetics.com/
